Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

24 May 2016

Abstract excerpt

The promise of tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADC) has now been realized, evidenced by the approval of two ADCs, both of which incorporate highly cytotoxic tubulin-interacting agents, for cancer therapy. An ongoing challenge remains in identifying potent agents with alternative mechanisms of cell killing that can provide ADCs with high therapeutic indices and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Click Chemistry and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27216304
DOI: 10.1158/1535-7163.mct-16-0184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating ActivityPMID 27216304Read ↗

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates LibrarySemantic proximity Read ↗

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.Semantic proximity Read ↗

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsSemantic proximity Read ↗

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceSemantic proximity Read ↗

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read ↗

Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.Semantic proximity Read ↗

Current ADC Linker ChemistrySemantic proximity Read ↗

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read ↗

<i>In Vivo</i> Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft modelSemantic proximity Read ↗

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Antibody-mediated co-delivery of programmable drug combinationsSemantic proximity Read ↗

Targeted Nanoparticles: an Innovative Modality in the Treatment of CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.